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Abstract: Three new homo-adamantanyl type natural products were derived from polyprenylated polycyclic acylphloroglucinol.  
Hypercohones A–C (1–3), along with five other known hypercohones (4–8), were isolated from the aerial parts of Hypericum  
cohaerens. The structures of 1–3 were elucidated on the basis of comprehensive spectroscopic analysis. The inhibitory activities of 
these isolates against five human cancer cell lines in vitro were tested. 
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Introduction 
Adamantanes, featured with a “diamond-like” caged core, 
have been of interest to medicinal chemists since the early 
1960s, when they were first used clinically for the treatment of 
influenza in the form of amantadine.1,2 In the past 50 years, 
adamantanes have yielded many compounds directed toward 
many different drug targets. Based on our detailed literature 
research, the adamantyl group was present in seven registered 
therapeutic compounds used currently for clinical use, and in 
many more compounds that were currently being developed as 
potential agents for the treatment of conditions such as iron 
overload disease, cancer, malaria and tuberculosis.3,4 In many 
cases, the adamantyl group has been found to increase  
drug-like qualities of a lead compound without increasing 
toxicity. The value of the adamantyl group in drug design is 
multi-dimensional. From a medicinal chemist’s point of view, 
the adamantyl group can be used either as a scaffold for the 
development of therapeutic agents, (i.e. memantine and  
amantadine), or as a modifier of the pharmacokinetics of a 
compound.1–4 
It was once assumed that living organisms could not  
synthesize adamantane derivatives, whose synthesis was  
considered purely abiotic. This view was finally refuted in 
1996 when pukenetione A, the first adamantane derivative 
isolated and identified from the plant Clusia plukenetii  
(Guttiferae).5,6 To date, less than 50 natural products with  
adamantane core skeletons have been reported. All of these 
compounds were characterized from the Guttiferae (Clusiaceae) 
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polycyclic acyphloroglucinols (PPAPs).7–9 Natural adaman-
tanes can be divided into two types based on their structural 
characteristics; adamantane and homo-adamantane. The two 
types of metabolites were both derived from polyprenylated 
polycyclic acyphloroglucinols by the further cyclizations of  
C-3 to the different position of prenyl groups at C-7  
(Figure 1).10–12 
The genus Hypericum, occurrs commonly in temperate  
regions throughout the world, and has been a key plant used in 
traditional medical systems in many countries.13 H. cohaerens 
N. Robson is an endemic plant distributed in Guizhou and 
Yunnan provinces of China.14 Previous phytochemical  
investigation of this plant led to the isolation of hypercohin A, 
a polyprenylated acylphloroglucinol derivative featuring with 
an unusual bicyclo[5.3.1]-hendecane core.15 With the aim of 
searching for bioactive and structural interesting 
acylphloroglucinol derivatives and continuing our systematic 
phytochemical studies of Hypericum spp. plants, the chemical 
constituents of this plant were investigated. In total, three new 
adamantyl type metabolites (hypercohones A–C, 1–3) were 
isolated, with an additional five known metabolites. Herein, 
this report describes the isolation and structural elucidation of 
these adamantyl type natural products from H. cohaerens. 
 
Results and Discussion 
The MeOH extract of the air-dried and powdered aerial 
parts of H. cohaerens (10.0 kg) was subjected to a silica gel 
column to afford five fractions A–E. Fraction B was subjected 
to a series of chromatographic methods, and led to the  
isolation of three new adamantyl acylphloroglucinol  
derivatives, namely hypercohones A–C (1–3), along with five 
known analogues, sampsonione D (4),16 sampsonione G (5),16 
plukenetione B (6),17 hypersampsone I (7),18 and sampsonione 
H (8).16 
Hypercohone A (1) was obtained as a colorless oil. Its  
molecular formula C33H42O5 was established by the positive 
HREIMS (m/z 518.3022, [M]+, calcd 518.3032), indicating 13 
degrees of unsaturation. The IR spectrum showed obvious 
absorption bands for carbonyl (1737 and 1703 cm–1) groups. 
Careful analysis of 13C and DEPT NMR data (Table 1)  
indicated that the characteristic signals for a benzoyl  
substituted adamantyl metabolite could be easily distinguished 
as below: three non-conjugated carbonyl (δC 204.9, C-2; δC 
204.6, C-4; and δC 206.6, C-9), four quaternary carbons at δC 
82.7 (C-1), 72.2 (C-3), 69.0 (C-5), and 49.0 (C-8), two  
methine at δC 43.4 (C-7) and 57.3 (C-28), one methylene at δC 
36.3 (C-6), and a benzoyl group (δC 194.3, C-10; δC 136.5,  
C-11; δC 129.6, C-12 and C-16; δC 129.3, C-13 and C-15; and δC 133.4, C-14).5–12 Obvious signals for an olefinic proton of 
isoprenyl group (δH 5.27, t, J = 7.5 Hz), eight methyls (δH 0.97 
–1.73, s), and a mono-substituted benzene group (δH 7.01, 2H, 
d, J = 8.3 Hz, H-12 and H-16; δH 7.31, 2H, dd, J = 8.3, 7.5 Hz, 
H-13 and H-15; δH 7.43, 1H, t, J = 7.5 Hz, H-14) could also be 
found in the 1H NMR spectrum (Table 2). These observations, 
conjugated with the fact that almost all of the natural adamantyl
compounds were isolated from the plants of Guttiferae family, 
indicated that 1 could be ascribed to be adamantyl or homo-
adamantyl type metabolites. The diagnostic signal found in the 
13C NMR spectrum at δC 23.6 (C-27) for a typical homo-
adamantyl type acylphloroglucinol suggested that 1 was a 
natural product with a homo-adamantane skeleton.10,11,16–18 
The 1H and 13C NMR spectral data of 1 were very similar to 
those of sampsonione G (5),16 indicating these two compounds 
shared a same planar structure. Biogenetically, the benzoyl 
group was usually located at C-1, which could be further evi-
denced by the chemical shift of C-1 (δC 82.7, s), otherwise the 
chemical shift might be in the upfield region. In the HMBC 
spectrum, the correlations from both Me-32 and Me-33 to C-1, 
C-7, and C-8, from both Me-30 and Me-31 to C-18, C-28, and 
C-29, from Me-20 and Me-21 to C-18, and C-19, from Me-25 
and Me-26 to C-23, and C-24, from H2-22 to C-4, C-5, C-6, 
and C-9, from H-6 to C-4, C-5, C-9, and C-27, as well as from 
H2-17 to C-2, C-3, C-4, C-19, and C-29 can all be found  
(Figure 2). These HMBC correlations, coupled with the proton 
spin systems H2-6/H-7/H2-27/H-28, H2-17/H-18, H2-22/H-23, 
 
Figure 2.  Key HMBC( ), 1H-1H COSY( ), and 
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Figure 1.  Plausible biogenetic pathway of adamantane and homo-adamantane type metabolites 
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and H-12/H-13/H-14/H-15/H-16 presented in the 1H-1H COSY 
spectrum (Figure 2), confirmed that 1 possessed a same planar 
structure with sampsonione G.16 
While side-by-side analysis of their NMR spectral data 
showed that the chemical shifts of C-17 (δC 31.5, t), C-27 (δC 
23.6, t), and C-31 (δC 17.4, q) of 1 were downfield shifted 
obviously in the 13C NMR spectrum compared to the  
corresponding signals of 5 (C-17, δC 33.1, t; C-27, δC 26.7, t; 
and C-31, δC 28.2, q). 
These observations indicated that 1 might be the stereo-
isomer of 5. In the ROESY spectrum of 5, diagnostic cross 
peaks of H-28/H-6b, H-28/H-30, and H-6a/Me-32 suggested 
the β-orientations of Me-30, Me-32, and H-28. All the ROESY 
correlations discussed above were almost identical with these 
of 5, which suggested the same configuration of 1 and 5 except 
for the stereochemistry of C-18. Then, H-18 was deduced to 
be β-oriented (Figure 2) by the ROESY correlations of  
H-18/H-28 and H-18/Me-30. Therefore, the structure of 1 was 
elucidated and named hypercohone A. 
Hypercohone B (2) was isolated as colorless oil and yielded 
a pseudomolecular ion peak at m/z 523.2811 ([M + Na]+, calcd 
523.2824) in the positive HRESIMS, indicative of the molecu-
lar formula C33H40O4. Comparison of their 1D and 2D NMR 
data indicated that the structures of 1 and 2 were very similar 
to each other (Tables 1 and 2). The difference lied in that the 
oxygenated quaternary carbon (C-19, δC 73.3, s) and Me-20 
(δC 30.8 q) in 1 were replaced by a double bond (δC 113.2, t, 
C-20; and 145.5, s, C-19) in 2, which could be confirmed by 
HMBC correlations from H-20 (δH 4.89 and 4.76, each 1H, br. 
s) to C-18 (δC 56.7, d), C-19, and C-21 (δC 23.7, q) and from 
Me-21 (δH 1.77, s) to C-18, C-19 and C-20. The ROESY cor-
relations of H-28/Me-30, H-28/H-6b, and H-6a/Me-32 showed 
that H-28, Me-30 and Me-32 were all β-oriented. Then H-18 
was elucidated to be in the α-orientation by its ROESY corre-
lations with Me-31 (Figure 3). Thus, the structure of 2 was 
established as shown. 
Hypercohone C (3) had a molecular formula of C38H48O4 
from the HRESIMS, 68 mass units more than 2, in accordance 
with the presence of an additional isoprenyl group. The 1D 
NMR data of 3 were similar to those of 2, with the only differ-
ence being the presence of five more signals ascribable for an 
isoprenyl group at δC 27.1 (t, C-34), 124.9 (d, C-35), 131.7 (s, 
C-36), 26.0 (q, C-37), and 17.7 (q, C-38). This isoprenyl group 
was ascribed to connect to C-25 by the HMBC correlations of 
Me-26 to C-24 and C-25, of both Me-37and Me-38 to C-35 
and C-36, coupled with the correlations of H2-25/H2-34 and 
H2-34/H-35 observed in the 1H-1H COSY spectrum. The 
ROESY correlations of H-28/Me-30, H-28/H-6b, H-6a/Me-32, 
and H-18/Me-31 showed that 3 had the same relative configu-
rations as 2. Accordingly, the structure of 3 was established 
and named hypercohone C. 
The AChE inhibitory activity of all the new and known 
compounds was assayed using the method developed by 
Ellman et al.19 None of these isolates showed any activities at 
the concentration of 50 μM. In addition, the eight isolates were 
Table 1. 13C NMR data for compounds 1–3 (δ in ppm, 150 MHz) 
position 1a 2b 3b position 1a 2b 3b 
1 82.7 C 82.7 C 82.7 C 21 30.0 CH3 23.7 CH3 23.7 CH3 
2 204.9 C 205.6 C 205.6 C 22 30.3 CH2 30.3 CH2 30.3 CH2 
3 72.2 C 73.0 C 73.0 C 23 120.3 CH 120.0 CH 120.1 CH 
4 204.6 C 203.8 C 203.8 C 24 136.1 CH 135.4 C 139.2 CH 
5 69.0 C 68.5 C 68.6 C 25 26.3 CH3 26.2 CH3 40.7 CH2 
6 36.3 CH2 35.3 CH2 35.2 CH2 26 18.2 CH3 18.0 CH3 16.3 CH3 
7 43.4 CH 42.9 CH 42.9 CH 27 23.6 CH2 26.6 CH2 26.6 CH2 
8 49.0 C 48.0 C 48.0 C 28 57.3 CH 55.1 CH 55.1 CH 
9 206.6 C 205.8 C 205.7 C 29 47.5 C 45.1 C 45.1 C 
10 194.3 C 193.8 C 193.8 C 30 29.5 CH3 28.0 CH3 28.0 CH3 
11 136.5 C 136.0 C 136.0 C 31 17.4 CH3 26.0 CH3 25.9 CH3 
12(16) 129.6 CH 129.1 CH 129.1 CH 32 25.6 CH3 25.2 CH3 25.3 CH3 
13(15) 129.3 CH 129.1 CH 129.1 CH 33 22.8 CH3 22.6 CH3 22.6 CH3 
14 133.4 CH 133.2 CH 133.2 CH 34   27.1 CH2 
17 31.5 CH2 34.4 CH2 34.4 CH2 35   124.9 CH 
18 60.8 CH 56.7 CH 56.7 CH 36   131.7 C 
19 73.3 C 145.5 C 145.5 C 37   26.0 CH3 
20 30.8 CH3 113.2 CH2 113.2 CH2 38   17.7 CH3 
aRecorded in methanol-d4; bRecorded in acetone-d6. 
 
Figure 3  Key ROESY correlations of 2 
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also tested for their cytotoxic effects against five human can-
cer cell lines, HL-60, A-549, SMMC-7721, MCF-7, and 
SW480, using the MTT method described previously.20 All the 
tested samples showed no activities against the mentioned cell 
lines with IC50 > 40 μM. 
 
Experimental Section 
General Experimental Procedures. Optical rotations were 
measured on a JASCO P-1020 polarimeter. UV spectra were 
detected on a Shamashim UV 2401 spectrometer. IR spectra 
were determined on a Broker Tensor-27 infrared spectropho-
tometer with Br disks. 1D and 2D NMR spectra were recorded 
on DRX-600 spectrometers using TMS as an internal standard. 
Unless otherwise specified, chemical shifts (δ) were expressed 
in ppm with reference to the solvent signals. ESIMS analysis 
and HREIMS were determined carried out on a Waters Auto 
spec Premier P776 mass spectrometer. Semi-preparative 
HPLC was performed on an Agile 1100 HPLC with a  
Razorback SB-C18 (9.4 mm × 25 cm) column. Silica gel (100–
200 and 200–300 mesh, Qingdao Marine Chemical Co., Ltd., 
Qingdao, China), and Amphichroic RP-18 gel (40–63 μm, 
Merck, Darmstadt, Germany) and MCI gel (75–150 μm, 
Mitsubishi Chemical Corporation, Tokyo, Japan) were used 
for column chromatography. 
 
Plant Material. The aerial parts of H. cohaerens N. Robson 
were collected in Daguan prefecture, Yunnan Province, China, 
in October 2009. The plant was identified by Dr. En-De Liu, 
Kunming Institute of Botany, Kunming, China. A voucher 
specimen was deposited with Kunming Institute of Botany 
with identification number 200910H01. 
 
Extraction and Isolation. The aerial parts of H. cohaerens 
(10.0 kg) were powdered and percolated with MeOH at room 
temperature and filtered. The filtrate was evaporated in vacuo 
to be concentrated. The obtained crude extract was subjected 
to a silica gel column chromatography eluted with petroleum 
ether-Me2CO in gradient to produce five fractions; A–E.  
Fraction B (86.4 g) was separated over a MCI-gel column 
(MeOH-H2O from 8:2 to 10:0) to obtain five fractions (B1–
B5). Fr. B1 (18.5 g) was then chromatographed on a silica gel 
column, eluted with petroleum ether-Me2CO (from 50:1 to 
10:1), to yield four fractions (B1a–B1d). Fr. B1a (9.3 g) was 
repeatedly subjected to silica gel columns, eluted with  
petroleum ether-EtOAc (from 50:1 to 6:1) and then was  
further purified by semi-preparative HPLC (MeOH-H2O, 95:5) 
to afford 2 (4 mg), 3 (4 mg), sampsonione D (4, 2 mg), hyper-
sampsone I (7, 8 mg) and sampsonione H (8, 3 mg). Fr. B3 
was separated over a MCI-gel column (MeOH-H2O from 
85:15 to 100:0) to obtain five fractions (Fr. B3a–B3e). Fr. B3b 
was then chromatographed on a silica gel column, eluted  
with petroleum ether-Me2CO (from 9:1 to 7:3), to yield seven 
fractions (Fr. B3b1–B3b7). Compounds 1 (20 mg),  
Plukenetione B (6, 20 mg) and sampsonione G (5, 13 mg) 
were isolated from Fr. B3b3 (200 mg) by chromatographed on 
C18 silica gel columns, silica gel columns and repeated semi-
preparative HPLC. 
 
Hypercohone A (1): colorless oil; [α] 22D   + 3.87 (c 0.21, 
MeOH); UV (MeOH) λmax ( log ε) 274 (3.7), 224 (4.5), 202 
(4.8) nm; IR (Br) νmax 3446, 2974, 2926, 2874, 1728, 1667, 
1621, 1468, 1368 cm–1; 1H and 13C NMR data, see Tables 1 
and 2; positive ESIMS m/z 541 [M + Na]+; HREIMS m/z 
518.3022  (calcd for C33H42O5 [M]+, 518.3032). 
 
Hypercohone B (2): colorless oil; [α] 24D   – 37.2 (c 0.11, 
MeOH); UV (MeOH) λmax (log ε) 245 (4.1) and 207 (4.2) nm; 
IR (KBr) νmax  2962, 2925, 1736, 1703, 1686，1637, 1448, 
1390 and 1236 cm–1; 1H and 13C NMR data, see Tables 1 and 2; 
positive ESIMS m/z 523 [M + Na]+; HRESIMS m/z 523.2811  
(calcd for C33H40O4Na [M + Na]+, 523.2824 ). 
 
Hypercohone C (3): colorless oil; [α] 24D   – 38.0 (c 0.09, 
MeOH); UV (MeOH) λmax ( log ε) 245 (4.2) and 207 (4.4) nm; 
IR (KBr) νmax 2962, 2926, 1736, 1703, 1686, 1448, 1390 and 
1235 cm–1; 1H and 13C NMR data, see Tables 1 and 2; positive 
ESIMS m/z 591 [M + Na]+; HRESIMS m/z 591.3446 (calcd 
for C38H48O4Na [M + Na]+, 591.3450 ). 
 
Table 2. 1H NMR data for compounds 1–3 (600 MHz, δ in ppm, 
J in Hz) 
pos. 1a 2b 3b 
6a 2.46 m 2.51 m 2.53 overlap
6b 2.34 d (13.2) 2.44 m 2.43 m 
7 2.17 m 2.24 m 2.24 m 
12(16) 7.01 d (8.3) 7.10 d (8.3) 7.10 d (8.3) 
13(15) 7.31 dd (8.3, 7.5) 7.38 dd (8.3, 7.5) 7.38 dd (8.3, 7.2) 
14 7.43 d (7.5) 7.48 t (7.5) 7.48 t (7.2) 
17 2.52 overlap 2.86 overlap 2.88 overlap 
 2.50 overlap 1.68 overlap 1.69 dd (13.2, 6.6)
18 1.82 dd (13.2, 7.2) 3.00 dd (12.6, 6.0) 3.01 dd (12.6, 6.6)
20 1.28 s 4.89 br. s 4.89 br. s 
  4.76 br. s 4.76 br. s 
21 1.32 s 1.77 s 1.77 s 
22 2.57 dd (15.3, 7.5) 2.59 m 2.61 dd (15.0, 7.5)
 2.50 overlap 2.54 m 2.55 overlap 
23 5.27 t (7.5) 5.27 t (7.5) 5.30 t (7.5)
25 1.73 s 1.70 s 2.02 overlap 
26 1.68 s 1.66 s 1.67s 
27 1.91 dd (13.9, 12.6) 2.04 overlap 2.05 overlap 
 1.76 m 1.95 m 1.95 m 
28 1.98 dd (12.6, 6.0) 2.29 dd (12.6, 7.8) 2.28 dd (12.3, 7.5)
30 1.11 s 0.85 s 0.85 s 
31 0.97 s 1.02 s 1.02 s
32 1.37 s 1.38 s 1.40 s 
33 1.34 s 1.36 s 1.36 s 
34   2.08 m 
35   5.08 t (6.9) 
37   1.64 s 
38   1.57 s 
aRecorded in methanol-d4; bRecorded in acetone-d6. 
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Acetylcholinesterase Inhibitory Activity. Acetylcholines-
terase inhibitory activity of the compounds was assayed by the 
spectrophotometric method developed by Ellman et al. 
Acetylthiocholine iodide (Sigma) was used as substrate in the 
assay. Compounds were dissolved in DMSO. The reaction 
mixture contained 1100 μL of phosphate buffer (pH 8.0), 10 
μL of test compound solution (50 μM), and 40 μL of acetyl 
cholinesterase solution (0.04 U/100 μL), and the mixture was 
incubated for 20 min (30 °C). The reaction was initiated by the 
addition of 20 μL of DTNB (6.25 mM) and 20 μL of 
acetylthiocholine. The hydrolysis of acetylthiocholine was 
monitored at 405 nm after 30 min. Tacrine was used as  
positive control. All the reactions were performed in triplicate. 
The percentage inhibition was calculated as follows: %  
inhibition ) (E – S)/E × 100 (E is the activity of the enzyme 
without test compound and S the activity of enzyme with test 
compound). 
 
Cytotoxcity Assays. The following human tumor cell lines 
were used: HL-60, SMMC-7721, A-549, MCF-7, and SW-480, 
which were obtained from ATCC (Manassas, VA, USA). All 
cells were cultured in RPMI-1640 or DMEM medium (Hy-
clone, Logan, UT, USA), supplemented with 10% fetal bovine 
serum (FBS, Hyclone) at 37 °C in a humidified atmosphere 
with 5% CO2. Cell viability was assessed by conducting color-
imetric measurements of the amount of insoluble formazan 
formed in living cells based on the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Sigma, St. Louis, MO, USA).17 Briefly, 100 μL of adherent 
cells was seeded into each well of a 96-well cell culture plate 
and allowed to adhere for 12 h before test compound addition, 
while suspended cells were seeded just before test compound 
addition, both with an initial density of 1 × 105 cells/mL in 
100 μL of medium. Each tumor cell line was exposed to the 
test compound at various concentrations in triplicate for 48 h, 
with cis-platin and paclitaxel (Sigma) as positive control. After 
the incubation, MTT (100 μg) was added to each well, and the 
incubation continued for 4 h at 37 °C. The cells were lysed 
with 100 μL of 20% SDS−50% DMF after removal of 100 μL 
of medium. The optical density of the lysate was measured at 
595 nm in a 96-well microtiter plate reader (Bio-Rad 680). 
The IC50 value of each compound was calculated by Reed and 
Muench’s method. 
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